News Search Results
Oct 21, 2024, 07:05 ET REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024
ABBV-RGX-314 in patients with bilateral wet age-related macular degeneration (wet AMD). The new data were presented at the American Academy of Ophthalmology (AAO) meeting by Arshad Khanani, M.D., M.A., FASRS, Director of Clinical Research at Sierra Eye Associates, Reno,
More news about: REGENXBIO Inc.
Oct 21, 2024, 07:00 ET HuidaGene Therapeutics Appoints TJ Cradick, PhD as Chief Technology Officer to Lead Delivery Science and Genome Editing Innovations
RNA-editing therapy for Alzheimer's. With an extensive intellectual property portfolio, HuidaGene is a leader in genome medicines for neurology and ophthalmology. Learn more at
More news about: HuidaGene Therapeutics
Oct 18, 2024, 10:09 ET Ace Vision Group Names David Lin, MD, as Chief Medical Advisor
currently Clinical Associate Professor of Ophthalmology, University of British Columbia; Fellow of the Royal College of Physicians and Surgeons of Canada; and certified by the American Board of Ophthalmology. "Throughout my career, I have
More news about: Ace Vision
Oct 18, 2024, 07:05 ET REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
evaluating subretinal delivery of ABBV-RGX-314 in patients with bilateral wet age-related macular degeneration (wet AMD) at the American Academy of Ophthalmology 2024 annual meeting. ABBV-RGX-314 is an investigational one-time AAV Therapeutic being developed in collaboration with AbbVie for the treatment
More news about: REGENXBIO Inc.
Oct 17, 2024, 17:02 ET Medical Coatings Market to Grow by USD 5.07 Billion from 2024-2028, Driven by Geriatric Population Growth and AI-Redefining the Market Landscape - Technavio
Biocoat Inc., provide advanced coating technologies like HYDAK hydrophilic coatings for neurovascular, cardiovascular, peripheral vascular, and ophthalmology applications. Single-layer coated formulations, which reduce particulate generation and offer superior lubricity compared to former hydrophilic
More news about: Technavio
Oct 17, 2024, 10:00 ET Nikon Small World Competition Celebrates 50 Years with Groundbreaking Image of Brain Tumor Cells
Waxman & Dr. Ian SigalUniversity of PittsburghDepartment of OphthalmologyPittsburgh, Pennsylvania, USAOptic nerve head collagen of a pigImage Stacking, Multiphoton25X
More news about: Nikon Instruments Inc.
Oct 17, 2024, 09:00 ET American Academy of Ophthalmology Launches VR Education Program in Collaboration with FundamentalVR to Improve Ophthalmic Care Around the World
areas of pediatric ophthalmology. For those who don't have access to a VR headset, a desktop version of the ROP simulator will be available later this year. About the American Academy of OphthalmologyThe American Academy of Ophthalmology is the world's largest
More news about: American Academy of Ophthalmology; FundamentalVR
Oct 16, 2024, 20:00 ET Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Ulcerative Colitis Met Primary Endpoint
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that primary endpoint of 12-week induction period was met in a multicenter, randomized, double-blind, placebo-controlled
More news about: Innovent Biologics
Oct 15, 2024, 12:46 ET RevOpsis Therapeutics Awarded $1.8M NEI SBIR Grant to Advance R&D for Groundbreaking Ophthalmic Therapies
compatibility, the RevMod platform enables swift and efficient design of multispecific biologics to address unmet needs in major therapeutic areas including ophthalmology, oncology, and immune-mediated diseases. About RevOpsis TherapeuticsFounded in 2018, RevOpsis Therapeutics is a privately
More news about: RevOpsis
Oct 15, 2024, 10:00 ET Beacon Therapeutics Announces Positive 24-Month Data from Phase 2 SKYLINE Trial of AGTC-501 in Patients with X-Linked Retinitis Pigmentosa
the Phase 2 SKYLINE Trial. Presenting Author – Robert Sisk, MD, FACS, FASRS, Associate Professor of Ophthalmology at the University of Cincinnati; Vitreoretinal Surgeon and partner at Cincinnati Eye Institute; Director of Pediatric
More news about: Beacon Therapeutics Holdings Limited
Oct 15, 2024, 09:00 ET Bloomage Debuts New Products at CPHI Milan to Reinforce Its Commitment to Innovation
effectively kill microorganisms, it can also break down HA due to the material's heat sensitivity, reducing its performance in applications such as ophthalmology and orthopedics. Conversely, Bloomage's new Hyatrue® Sterile Sodium Hyaluronate is sterilized using a cutting-edge filtration
More news about: Bloomage
Oct 15, 2024, 08:00 ET MAINEGENERAL HEALTH IN THE US SELECTS SECTRA'S ENTERPRISE IMAGING SAAS TO HELP RADIOLOGISTS IMPROVE DIAGNOSTIC SPEED DESPITE GROWING DEMANDS
worldwide. Sectra offers a complete enterprise solution comprised of imaging modules (radiology, cardiology, pathology, orthopedics, and ophthalmology), and a robust VNA. Over the last consecutive eleven years, Sectra has been awarded Best in KLAS for highest
More news about: Sectra, Inc
Oct 15, 2024, 07:00 ET Nanoscope Announces Presentations at the American Academy of Ophthalmology Annual Meeting 2024
multimedia:https://www.prnewswire.com/news-releases/nanoscope-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2024-302273411.html
More news about: Nanoscope Therapeutics
Oct 15, 2024, 00:01 ET Accelerated Three-Year Medical School Students Perform as Well as Peers in Traditional Four-Year Programs
they proceed directly to a residency here or get matched elsewhere." Cohen is a professor and vice chair for academic affairs in the Department of Ophthalmology at NYU Grossman School of Medicine and is the advisor to its accelerated students. Although graduates of the condensed program scored equally
More news about: NYU Grossman School of Medicine and NYU Langone Health
Oct 14, 2024, 21:51 ET PharmAbcine Announces Safety Approval for 4mg Single-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration
efficacy of the 4mg multiple-dose cohort. The Company expects PMC-403 to play a pivotal role in the global market for AMD treatments. Beyond ophthalmology, PMC-403 is being explored in therapeutic areas, including vascular-related rare diseases, Acute Respiratory Distress Syndrome, Inflammatory Bowel
More news about: PharmAbcine
Oct 14, 2024, 17:35 ET Kodiak Sciences to Present at Innovate Retina 2024
3:30 PM CTPresenter: Mark Barakat, M.D., FASRS, Clinical Assistant Professor of Ophthalmology, University of Arizona College of Medicine – Phoenix; Founder and Director of Research,
More news about: Kodiak Sciences Inc.
Oct 14, 2024, 17:05 ET Ophthalmology Devices Market projected to grow by USD 19.1 Billion from 2024-2028, driven by AI-powered innovations and rising prevalence of ophthalmic diseases - Technavio
Segment Overview This ophthalmology devices market report extensively covers market segmentation by Product 1.1 Vision care1.2 Ophthalmology surgical devices1.3 Ophthalmology diagnostic devicesEnd-user
More news about: Technavio
Oct 10, 2024, 09:00 ET AEYE Health's Portable Autonomous AI Screening Solution for Diabetic Retinopathy to Be Showcased at AAO, CPCA, AAHCM, and HLTH 2024
American Academy of Ophthalmology (AAO) Annual MeetingAEYE Health will attend the AAO Annual Meeting, from October 18-21 in Chicago.
More news about: AEYE Health
Oct 10, 2024, 08:00 ET Beyeonics One Revolutionizes Ophthalmic Surgery with Invisible Light Technology
Oct. 10, 2024 /PRNewswire/ -- Beyeonics Vision a leading innovator in digital visualization technology for Ophthalmology, proudly announces the launch of Beyeonics One, now featuring cutting-edge invisible light, based on infrared night-vision technology. This advanced
More news about: Beyeonics
Oct 10, 2024, 07:00 ET InMode to Report Third Quarter 2024 Financial Results and Hold Conference Call on October 30, 2024
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
More news about: InMode LTD
Oct 10, 2024, 06:52 ET Mallinckrodt Announces an Expanded Rollout of the INOmax® EVOLVE™ DS Delivery System in U.S. Hospitals
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; and gastrointestinal products. Its Specialty Generics
More news about: Mallinckrodt plc
Oct 09, 2024, 09:00 ET ZEISS expands ophthalmic offerings to improve patient care with new digital AI tools and revolutionary surgical solutions
American Academy of Ophthalmology (AAO) conference from Oct. 19-21, 2024, in Chicago. These innovations across
More news about: Carl Zeiss Meditec AG
Oct 09, 2024, 09:00 ET ZEISS expands ophthalmic offerings to improve patient care with new digital AI tools and revolutionary surgical solutions
American Academy of Ophthalmology (AAO) conference from Oct. 19-21, 2024, in Chicago. These innovations across
More news about: Carl Zeiss Meditec AG
Oct 08, 2024, 08:00 ET MellingMedical Expands Its Suite of Ophthalmological Offerings with Iantrek's Cutting Edge Solutions
highly practical and specialized to meet patient needs," said Iantrek founder, Sean Ianchulev, MD MPH, Professor of Ophthalmology at New York Eye and Ear of Mount Sinai. "We believe our products can have the maximum impact on the biggest patient base, so we're grateful for
More news about: MellingMedical
Oct 08, 2024, 07:00 ET Emmecell Completes Last Patient Last Visit for Proof-of-Concept Trial of Groundbreaking Cell Therapy for Corneal Edema
without surgery would be a game-changer for patients suffering with corneal edema," said Ellen Koo, MD, professor of ophthalmology at the Bascom Palmer Eye Institute, University of Miami, and an investigator in the study. "Currently, for patients
More news about: Emmecell